Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (127)	1/16/2002 8:11:50 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 598

You guys are confusing me. From HnQ: My paraphrase re: T67: P2 in hepatocellular has enrolled but is not completed, but they are going ahead in HCC 'no matter what' because P1 and P2 (safety, I take it) looks good enough and it's a tough cancer when finally diagnosed. Have decided to meet with FDA 1Q02 (maybe Feb.) to discuss going pivotal or continuing the program as planned. Said again later that one 2002 milestone will be P3 in HCC with T67. My paraphrase re: T607: P1 taking longer because they keep moving to higher doses. They see activity in HCC too. Almost completed P1. Pursuing HCC, NHL, and GI. I probably ought to own some tlrk, but I don't have such good luck buying $1b BTs. Awfully nice how they mostly own everything still. Wilder